Intravitreal Bevacizumab for Treatment of Refractory Central Serous Choroidoretinopathy
In a clinical case series, 5 patients with not-resolved central serous choroidoretinopathy (CSC) lasting more than 1 year received one intravitreal bevacizumab injection (IVB, 1.25 mg) injection. All patients underwent a through ophthalmic examination 1 day, 1 week, and 1, 2, and 6 months after the...
| Main Authors: | , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
The Korean Ophthalmological Society
2012
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3325620/ |